End-Stage Kidney Disease Risk Assessment Test

Bio Preventive Medicine Co. Ltd.

Zhubei City, Hsinchu, Taiwan

Bio Preventive Medicine (BPM) is an innovative clinical-staged biotech company, focusing on early detection and prevention of diseases specialty of those high value added molecular diagnostic product. Started from an ITRI (a Taiwanese national lab and global top 100 innovator) spin-off in 2014 to launch the first product " DNlite ", BPM is now growing into a leading company in innovative renal diagnostic solution, with a GMP (Taiwan FDA) /QMS accredited plant & ISO 17025 accredited Lab Facilities at Hsinchu, Taiwan. The company has demonstrated excellence with domain expertise in translational research and IVD development, brought up a new revolutionary page of precision medicine. DNlite, an ELISA based non-invasive urinary test for monitoring the progression of Diabetic Nephropathy, is an effective tool for screening, detecting and monitoring kidney complications in diabetes. Unlike the current standard test (known as eGFR and UACR) can only detect the disease once it's already present, DNlite predicts kidney function loss years in advance. It can be also applied in CKD, AKD, and Kidney Transplant. In addition to diabetic nephropathy, the proprietary technology of BPM also include biomarker-based diagnostic technology for other chronic diseases and oncology. At Bio Preventive Medicine Corp. , we hold significant intellectual property rights for our clinically validated biomarker product and are very interested in pursuing business partnerships via licensing, co-development, clinical research projects, or product distribution.